A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Exclusion Criteria

• •Subjects must not have an ocular itching score \>0 or a conjunctival redness score \>1 prior to CAPT in either eye in any region (nasal or temporal) at Visits 2-4. I
• •History of glaucoma, or Intraocular Pressure (IOP) over 25mmHg at the screening visit, or a history of elevated IOP within the past 1 year.
• •Ocular surgery, including laser procedures, within the past 12 months of Visit 1.
• •Use of glaucoma medications, antibiotics, antivirals, or topical cyclosporine within 1 month of the screening visit.
• •History of dry eye syndrome, blepharitis, herpes simplex keratitis or herpes zoster keratitis.
• •History of uveitis in the past 3 years.
• •Presence of any ocular infection or active ocular inflammation (e.g. follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to start of study (Visit 1).
• •History of moderate to severe asthma or allergy induced asthma to the allergen that will be used in CAPT.
• •Use of oral corticosteroids within 30 days of screening and throughout the study period; use of intranasal or inhaled corticosteroids within 14 days of screening and throughout the study period.
• •Use of antihistamines (ocular, nasal, topical or oral) within 7 days prior to screening (Visit 1) and throughout the study period. Non-medicated artificial tears are allowed up to 72 hours before screening (Visit 1) and throughout the study period.